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unacceptably high. Identified biomarkers could also be a basis for
monitoring treatment and identifying resistance mechanisms.
One example for the need to identify biomarkers is immuno-
therapy. It is important to bear in mind that immune-mediated
anti-tumour reactivity is the result of a well-orchestrated interac-
tion of multiple factors and multiple pathways. Redundant path-
ways and interactions present a set of challenges when designing
immunotherapies or identifying surrogates. Studying any of the
multiple immunemediators in isolation offers little about efficacy
because of these interactions. Therefore a set of biomarkers is
expected to more and more replace single ones. Methods such
as proteomics need to be better standardised and validated as
they may speed up the identification of biomarkers and thus drug
development as a whole.
As soon as biomarkers have been fully validated, they have
the potential to be developed to surrogate markers. Surrogate
endpoints should be based on functional parameters of critical
importance for cancer control. Although functional parameter
techniques have been around for many years, they can provide
very useful information for molecularly targeted drug develop-
ment. Such parameters include cell proliferation, cell death,
inflammatory infiltration, and tumour regression.
For example, the immediate preoperative anastrozole, tamox-
ifen, or combined with tamoxifen (IMPACT) trial relied upon a
measure of proliferation – immunohistochemical assessment of
the nuclear antigen Ki-67 – as an endpoint.2,3 The method was
highly reproducible and predictive of therapeutic efficacy. Mohsin
et al.4 used another functional parameter – apoptosis – in a trial of
the neoadjuvant trastuzumab in 35 patients with locally
advanced Her-2/neu overexpressing breast cancers. They found
that induction of apoptosis correlated with tumour regression.
Tumour biopsies can be examined for inflammatory lympho-
cyte migration as another means of monitoring treatment effi-
cacy using functional parameters, as shown in one study
involving stage III melanoma patients treated with interferon-
alpha.5 Patients whose tumours demonstrated P2% CD4+
tumour-infiltrating lymphocytes (TIL’s) had prolonged time to
progression and improved overall survival compared with
patients whose tumours had < 2% TIL’s. Finally, tumour regressive
changes correlate with long-term survival. Overall survival in
metastatic melanoma patients has been shown to correlate with
tumour regressive changes.6
Trials that rely on functional parameter endpoints obviously
depend on the availability of tumour biopsies. Obtaining such
samples is critical for developing molecularly targeted therapies.
Stated otherwise, ‘No tissue – no trial’.7 For example, with biopsy
specimens, it would be possible to compare all phosphorylated
proteins in the tumours before and after treatment to observe
potential changes. Moreover, it is becoming more possible to pre-
dict response to immunotherapy based on tumour biopsies.
Therefore prognostic biomarkers also provide means for identify-
ing patients who might be at high risk of disease recurrence after
radical surgery and might be candidates for adjuvant therapy.
Predictive biomarkers could be used to discern which patients
would be more likely to respond to a particular therapy. Interleu-
kin-6 (IL-6) production by peripheral blood mononuclear cells
(PBMC’s) preoperatively collected from patients with primary
colorectal cancer predicts survival. Eight of 13 patients with
>5000 pg/mL IL-6 died from cancer within the 54-month follow-
up period, whereas no cancer-related deaths were recorded
among 21 patients with 5000 pg/mL IL-6 or less. A multivariate
Cox regression analysis, stratified for tumour and node stage,
identified IL-6 production as an independent prognostic factor.8
In conclusion, molecularly targeted treatment of cancer is
sometimes criticised for poor therapeutic efficacy. Among the
reasons that it has not met with greater success are reliance upon
suboptimal dosing, the fact that molecular targets are not always
the therapeutic target, pathway redundancy, and resistance
mechanisms. However, molecularly targeted treatment of cancer
is still at a very early stage; there is a great need to identify rele-
vant therapeutic targets and establish molecular and functional
surrogate endpoints. The techniques are available the time to
design the respective clinical trials is now.
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In the context of biomarkers, antibodies fall into four main cate-
gories, each of which carries a different level of risk from an eco-
nomic development point of view (Fig. 1). Those markers used for
routine diagnostic purposes entail little or no risk, and prognostic
markers involve high risk. Predictive markers associated with
established therapies are low risk whereas those for new thera-
pies involve high risk.
The focus of the presentation was on development of antibod-
ies for detecting cancer biomarkers. It is crucial to use prospec-
tively defined criteria to select patients who are most likely to
respond to a specific molecularly targeted therapy. Proper patient
selection enables efficient clinical trial design for targeted thera-
pies and ensures that the number of individuals exposed to the
risks of anticancer therapy is minimised.
Patient selection can be facilitated through the use of systems,
such as pharmDx, Dako’s complete diagnostic assays that enable
selection of patients more likely to benefit from targeted therapy.
Herceptest was the first such system developed. It is used to
identify patients whose tumours overexpress Her-2/ERB2 and,
therefore, who would be mostly likely to respond to treatment
with trastuzumab (Herceptin), a humanised antibody targeting
the HER-2 receptor. By screening with the pharmDx system, the
response rate is greater than if the general patient population
were treated with trastuzumab. Semiquantitative scaling was
used for registration of the pharmDx technique and is the basis
for its labelling.
The quality of antibodies under development in terms of sen-
sitivity and specificity is extremely important. Antibodies can be
developed internally or acquired from external sources, usually
from the university research community. No matter how antibod-
ies are developed, they must be of the best quality with no toler-
ance for variation between batches.
Screening systems are required to ensure quality and
researchers use additional quality testing to ensure that the anti-
bodies actually recognise the specific moieties. Epitope mapping
is necessary to ensure specificity. Many antibodies on the market
have different specificities; this fact must be taken into account
when using them to select patients. The shelf life of Dako anti-
bodies is usually about 2 years. Detection of activated (phosphor-
ylated) proteins has received increasing interest during the last
few years. It is challenging to develop phospho-specific antibod-
ies that do not display cross-reactions with the backbone
sequence. The specificity, functionality, and the absence of
cross-reactions are verified by different methodologies to ensure
quality and performance of antibodies.
The antibodies must work on different types of tissues. This
needs to be confirmed by testing in multi-tissue arrays to make
sure that background staining is not problematic. The final step
is standardization of the assay to ensure consistency across
laboratories.
In conclusion, the keys to successful development of antibod-
ies for use in patient selection are high quality – in terms of spec-
ificity, functionality, and sensitivity – and standardisation of
reagents (no batch-to-batch variation), automated protocols,
and use of imaging as a means of interpreting the response.
Developing antibody-based testing for biomarkers is a high-risk
area, but the potential benefits are significant. Regulatory author-
ities throughout the world strongly advocate standardization of
testing to minimise the number of patients who experience
adverse side effects from treatment. Proper patient selection
can also optimise treatment expenditures by selecting the patient
population most likely to respond.
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The goal of incorporating biomarkers into cancer treatment and
clinical trials is to manage a patient’s disease by administering
effective and well-tolerated therapies, based on an understanding
of the patient’s unique genetic and molecular profile. For targeted
therapies that might only benefit a proportion of patients, failure
to select patients correctly has the potential to dilute trial out-
comes. Challenges in identifying those patients most likely to
benefit might risk wrongly concluding that therapeutically bene-
ficial drugs are ineffective.
There are many types of biomarkers of potential interest in
the field of targeted anticancer therapy. These can mainly be
divided into those that present in histopathological tissues and
blood-borne biomarkers. Significant advances in imaging (e.g.,
positron emission tomography [PET] scans) have also improved
the ability to monitor treatment effects. The focus of the presen-
tation was on acquisition of histopathological tissues.
GEFITINIB (IRESSA) CLINICAL DEVELOPMENT: The clinical
development of gefitinib, an orally-available epidermal growth
factor tyrosine kinase inhibitor (EGFR TKI) was reviewed: Phase I
and II development showed dramatic and unexpected tumour









Fig. 1 – Strategies and challenges for cancer biomarker and
antibody development.
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